| Literature DB >> 29872056 |
Tasnime Akbaraly1,2,3,4,5, Peter Würtz6, Archana Singh-Manoux7,8, Martin J Shipley7, Rita Haapakoski7, Maili Lehto7, Catherine Desrumaux9,10,11, Mika Kähönen12, Terho Lehtimäki13, Vera Mikkilä14, Aroon Hingorani15, Steve E Humphries15, Antti J Kangas6, Pasi Soininen6,16, Olli Raitakari12,17, Mika Ala-Korpela6,16,18,19,20,21, Mika Kivimäki7,22.
Abstract
Diet may modify metabolomic profiles towards higher or lower cardiovascular disease (CVD) risk. We aimed to identify metabolite profiles associated with high adherence to dietary recommendations - the Alternative Healthy Eating Index (AHEI) - and the extent to which metabolites associated with AHEI also predict incident CVD. Relations between AHEI score and 80 circulating lipids and metabolites, quantified by nuclear magnetic resonance metabolomics, were examined using linear regression models in the Whitehall II study (n = 4824, 55.9 ± 6.1 years, 28.0% women) and were replicated in the Cardiovascular Risk in Young Finns Study (n = 1716, 37.7 ± 5.0 years, 56.3% women). We used Cox models to study associations between metabolites and incident CVD over the 15.8-year follow-up in the Whitehall II study. After adjustment for confounders, higher AHEI score (indicating healthier diet) was associated with higher degree of unsaturation of fatty acids (FA) and higher ratios of polyunsaturated FA, omega-3 and docosahexaenoic acid relative to total FA in both Whitehall II and Young Finns studies. A concordance of associations of metabolites with higher AHEI score and lower CVD risk was observed in Whitehall II. Adherence to healthy diet seems to be associated with specific FA that reduce risk of CVD.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29872056 PMCID: PMC5988716 DOI: 10.1038/s41598-018-26441-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of Whitehall II participants and Young Finns Study participants.
| Characteristics | Whitehall II | Young Finns Study | |||
|---|---|---|---|---|---|
| N | % or mean (SD) | N | mean ± SD or | ||
| Sex | Men | 3483 | 72.2 | 966 | 56.3 |
| Women | 1341 | 27.8 | 750 | 43.7 | |
| Age, years | 4824 | 55.9 (6.1) | 1716 | 37.7 (5.0) | |
| Ethnicity | White | 4541 | 93.9 | 1716 | 1716 (100.0) |
| South Asian | 183 | 3.9 | / | / | |
| Black | 100 | 2.2 | / | / | |
| Smoking habits | Non | 2490 | 52.1 | 886 | 51.6 |
| Former | 1864 | 39.1 | 421 | 24.5 | |
| Current | 470 | 8.9 | 409 | 23.8 | |
| Physical activity MET unit /hours/week | 4824 | 15.6 (14.8) | 1716 | 19.6 (21.5) | |
| Total score in AHEI, points | 4824 | 50.7 (9.8) | 1716 | 46.3 (8.0) | |
| Total energy intake, kcal/day | 4824 | 2233 (683) | 1716 | 2392 (800) | |
| Prevalent type 2 diabetes | No | 4528 | 93.9 | 1665 | 97.0 |
| Yes | 296 | 6.1 | 51 | 3.0 | |
| Systolic blood pressure, mmHg | 4824 | 123.1 (16.5) | 1716 | 120.3 (14.3) | |
| Diastolic blood pressure, mmHg | 4824 | 77.4 (10.5) | 1714 | 75.4 (11.4) | |
| Use of antihypertensive treatment | No | 4 229 | 87.4 | 1604 | 93.5 |
| Yes | 607 | 12.6 | 112 | 6.5 | |
| Triglycerides, mmol/L | 4823 | 1.35 (0.86) | 1714 | 1.38 (0.90) | |
| HDL-cholesterol, mmol/L | 4298 | 1.46 (0.39) | 1708 | 1.34 (0.32) | |
| Use of lipids lowering drugs | No | 4669 | 96.9 | 1686 | 98.2 |
| Yes | 155 | 3.1 | 30 | 1.7 | |
| Body mass index, kg/m² | 4175 | 26.0 (3.9) | 1695 | 25.8 (4.7) | |
Figure 1Age-, sex- and energy intake-adjusted associations between AHEI z-score and metabolites in Whitehall II study. Results are expressed as regression coefficients accompanied with their 95% confidence interval for one standard deviation increment in AHEI diet score. To facilitate comparison, metabolites were square root transformed and standardized to z-scores (mean = 0, SD = 1). P ≥ 0.0006; P < 0.0006.
Results of multivariable adjusted linear regression models of the association between AHEI z-score and the 42 selected metabolites in the Whitehall II study and in Young Finns Study.
| Multivariable-adjusted Model* | ||||||
|---|---|---|---|---|---|---|
| Whitehall II (N = 4699) | Young Finns Study (N = 1625) | |||||
| Beta | 95% CI | p | Beta | 95% CI | p | |
|
| ||||||
| Isoleucine | −0.044 | −0.072 to −0.017 | 0.002 | 0.011 | −0.034 to 0.056 | 0.64 |
| Leucine | −0.061 | −0.088 to −0.034 | 1*10−5 | 0.010 | −0.035 to 0.055 | 0.65 |
| Phenylalanine | −0.074 | −0.104 to −0.044 | 1*10−6 | −0.038 | −0.090 to 0.014 | 0.15 |
|
| ||||||
| Glycerol | −0.044 | −0.074 to −0.014 | 0.004 | −0.009 | −0.060 to 0.042 | 0.73 |
|
| ||||||
| Glycoprotein acetyls | −0.035 | −0.064 to −0.006 | 0.02 | −0.012 | −0.063 to 0.039 | 0.64 |
|
| ||||||
| VLDL particle size | −0.048 | −0.076 to −0.019 | 0.0009 | −0.003 | −0.051 to 0.046 | 0.91 |
| HDL particle size | 0.033 | 0.006 to 0.061 | 0.02 | −0.005 | −0.051 to 0.040 | 0.82 |
|
| ||||||
| Total lipids in chylomicrons and extremely large VLDL | −0.073 | −0.102 to −0.044 | 8*10−7 | −0.033 | −0.082 to 0.016 | 0.19 |
| Total lipids in very large VLDL | −0.061 | −0.089 to −0.032 | 4*10−5 | −0.022 | −0.070 to 0.027 | 0.38 |
| Total lipids in large VLDL | −0.049 | −0.078 to −0.021 | 0.0007 | −0.006 | −0.054 to 0.042 | 0.81 |
| Total lipids in medium VLDL | −0.036 | −0.067 to −0.008 | 0.01 | 0.001 | −0.048 to 0.048 | 0.99 |
| Total lipids in small VLDL | −0.019 | −0.048 to 0.010 | 0.21 | 0.017 | −0.031 to 0.065 | 0.49 |
| Total lipids in IDL | −0.039 | −0.069 to −0.010 | 0.01 | −0.032 | −0.084 to 0.021 | 0.24 |
| Total lipids in large LDL | −0.045 | −0.075 to −0.015 | 0.003 | −0.032 | −0.084 to 0.021 | 0.24 |
| Total lipids in medium LDL | −0.044 | −0.074 to −0.014 | 0.004 | −0.028 | −0.080 to 0.024 | 0.29 |
| Total lipids in small LDL | −0.039 | −0.069 to −0.009 | 0.01 | −0.028 | −0.080 to 0.023 | 0.28 |
| Total lipids in small HDL | −0.054 | −0.083 to −0.024 | 0.0003 | 0.001 | −0.052 to 0.054 | 0.96 |
|
| ||||||
| Cholesterol in VLDL | −0.036 | −0.065 to −0.006 | 0.02 | −0.006 | −0.055 to 0.043 | 0.81 |
| Remnant cholesterol (non−HDL, non−LDL −cholesterol) | −0.041 | −0.071 to −0.011 | 0.007 | −0.021 | −0.072 to 0.029 | 0.41 |
| Free cholesterol | −0.055 | −0.084 to −0.026 | 0.0002 | −0.035 | −0.089 to 0.018 | 0.19 |
|
| ||||||
| Serum total TG | −0.034 | −0.063 to −0.005 | 0.02 | −0.002 | −0.050 to 0.047 | 0.95 |
| TG in VLDL | −0.031 | −0.061 to −0.003 | 0.04 | 0.001 | −0.046 to 0.049 | 0.95 |
| TG in LDL | −0.031 | −0.060 to −0.002 | 0.04 | −0.012 | −0.064 to 0.041 | 0.66 |
| TG in HDL | −0.060 | −0.090 to −0.031 | 5*10−5 | −0.017 | −0.070 to 0.036 | 0.53 |
| Sphingomyelins | −0.081 | −0.110 to −0.053 | 2*10−8 | −0.022 | −0.074 to 0.031 | 0.42 |
|
| ||||||
| Saturated FA | −0.056 | −0.086 to −0.027 | 0.0002 | −0.029 | −0.080 to 0.022 | 0.27 |
| Monounsaturated FA | −0.069 | −0.098 to −0.040 | 2*10−6 | −0.022 | −0.072 to 0.028 | 0.39 |
| Polyunsaturated FA | 0.076 | 0.047 to 0.106 | 4*10−7 | 0.028 | −0.025 to 0.080 | 0.30 |
| Omega-3 FA | 0.140 | 0.111 to 0.169 | 1*10−20 | 0.097 | 0.045 to 0.149 | 0.0003 |
| docosahexaenoic acid | 0.176 | 0.147 to 0.205 | 1*10−32 | 0.096 | 0.044 to 0.149 | 0.0003 |
| Omega-6 FA | 0.054 | 0.024 to 0.083 | 0.0004 | 0.009 | −0.043 to 0.062 | 0.72 |
| linoleic acid | 0.076 | 0.046 to 0.105 | 6*10−7 | 0.004 | −0.049 to 0.056 | 0.89 |
| Conjugated linoleic acid | −0.198 | −0.227 to −0.169 | 2*10−40 | NA | NA | |
|
| ||||||
| Estimated degree of unsaturation | 0.210 | 0.183 to 0.238 | 1*10−48 | 0.116 | 0.066 to 0.166 | 5*10−6 |
| Ratio of saturated FA to total FA (%) | −0.164 | −0.194 to −0.134 | 4*10−27 | −0.089 | −0.141 to −0.037 | 0.0008 |
| Ratio of monounsaturated FA to total FA (%) | −0.124 | −0.152 to −0.095 | 2*10−17 | −0.034 | −0.082 to 0.015 | 0.17 |
| Ratio of polyunsaturated FA to total FA (%) | 0.194 | 0.162 to 0.219 | 2*10−41 | 0.082 | 0.033 to 0.131 | 0.0011 |
| Ratio of omega-3 FA to total FA (%) | 0.190 | 0.162 to 0.219 | 1*10−37 | 0.142 | 0.091 to 0.193 | 5*10−8 |
| Ratio of docosahexaenoic acid to total FA (%) | 0.220 | 0.192 to 0.249 | 9*10−52 | 0.139 | 0.090 to 0.189 | 4*10−8 |
| Ratio of omega-6 FA to total FA (%) | 0.137 | 0.109 to 0.166 | 6*10−21 | 0.044 | −0.006 to 0.094 | 0.08 |
| Ratio of linoleic acid to total FA (%) | 0.145 | 0.116 to 0.174 | 1*10−22 | 0.029 | −0.022 to 0.080 | 0.26 |
| Ratio of conjugated linoleic acid to total FA (%) | −0.226 | −0.255 to −0.197 | 7*10−52 | NA | NA | / |
*Multivariable adjusted model: adjusted for age, sex, total energy intake, ethnicity, smoking habits, physical activity, type 2 diabetes, diastolic and systolic blood pressure, use of antihypertensive drugs and use of lipid-lowering drugs. Results were expressed as linear regression coefficients accompanied with their 95% confidence interval. Analyses were carried out on participants for which all metabolites measurement were available.
Figure 2Multivariable-adjusted associations between AHEI z-score and metabolites from meta-analysis of the Whitehall II Study and the Young Finns Study (YFS). Whitehall II study; YFS; Meta-analysis. Linear regression models were adjusted for age, sex, total energy intake, ethnicity, smoking habits, physical activity, type 2 diabetes, diastolic and systolic blood pressure, use of antihypertensive drugs and use of lipid-lowering drugs. Results are expressed as linear regression coefficients accompanied with their 95% confidence interval. To facilitate comparison, metabolites were first square root transformed and then standardized to z-scores (mean = 0, SD = 1).
Association between baseline metabolites and incident cardiovascular disease over 15.8 years of follow-up in the Whitehall II study.
| Association with CVD risk (total N = 5481; N incident cases = 697) | |||
|---|---|---|---|
| Hazard Ratio* | 95% CI | p | |
|
| |||
| Isoleucine | 1.14 | 1.06 to 1.24 | 0.001 |
| Leucine | 1.13 | 1.04 to 1.22 | 0.003 |
| Phenylalanine | 1.14 | 1.07 to 1.23 | 0.000 |
|
| |||
| Glycerol | 1.06 | 0.98 to 1.14 | 0.14 |
|
| |||
| Glycoprotein acetyls | 1.20 | 1.11 to 1.30 | 3*10−6 |
|
| |||
| VLDL particle size | 1.12 | 1.03 to 1.21 | 0.007 |
| HDL particle size | 0.86 | 0.79 to 0.94 | 0.0006 |
|
| |||
| Total lipids in chylomicrons and extremely large VLDL | 1.09 | 1.01 to 1.18 | 0.02 |
| Total lipids in very large VLDL | 1.09 | 1.01 to 1.17 | 0.03 |
| Total lipids in large VLDL | 1.12 | 1.03 to 1.21 | 0.005 |
| Total lipids in medium VLDL | 1.12 | 1.04 to 1.21 | 0.004 |
| Total lipids in IDL | 1.07 | 0.99 to 1.16 | 0.003 |
| Total lipids in large LDL | 1.09 | 1.01 to 1.18 | 0.01 |
| Total lipids in medium LDL | 1.09 | 1.01 to 1.18 | 0.08 |
| Total lipids in small LDL | 1.08 | 1.00 to 1.17 | 0.03 |
| Total lipids in small HDL | 0.97 | 0.90 to 1.05 | 0.02 |
|
| |||
| Cholesterol in VLDL | 1.09 | 1.01 to 1.18 | 0.03 |
| Remnant cholesterol (non-HDL, non-LDL -cholesterol) | 1.07 | 0.99 to 1.16 | 0.07 |
| Free cholesterol | 1.04 | 0.96 to 1.12 | 0.36 |
|
| |||
| Serum total TG | 1.15 | 1.07 to 1.24 | 0.0002 |
| TG in VLDL | 1.14 | 1.05 to 1.23 | 0.0013 |
| TG in LDL | 1.19 | 1.11 to 1.28 | 3*10−6 |
| TG in HDL | 1.13 | 1.04 to 1.22 | 0.0021 |
| Sphingomyelins | 0.98 | 0.90 to 1.06 | 0.56 |
|
| |||
| Saturated FA | 1.09 | 1.01 to 1.18 | 0.02 |
| Monounsaturated FA | 1.12 | 1.04 to 1.21 | 0.004 |
| Polyunsaturated FA | 1.05 | 0.97 to 1.13 | 0.26 |
| Omega-3 FA | 0.97 | 0.90 to 1.05 | 0.43 |
| docosahexaenoic acid | 0.96 | 0.89 to 1.04 | 0.33 |
| Omega-6 FA | 1.06 | 0.98 to 1.14 | 0.14 |
| linoleic acid | 1.06 | 0.98 to 1.14 | 0.14 |
| Conjugated linoleic acid | 1.05 | 0.97 to 1.13 | 0.23 |
|
| |||
| Estimated degree of unsaturation | 0.90 | 0.83 to 0.97 | 0.009 |
| Ratio of saturated FA to total FA (%) | 1.01 | 0.93 to 1.08 | 0.90 |
| Ratio of monounsaturated FA to total FA (%) | 1.11 | 1.03 to 1.21 | 0.007 |
| Ratio of polyunsaturated FA to total FA (%) | 0.90 | 0.84 to 0.97 | 0.009 |
| Ratio of omega-3 FA to total FA (%) | 0.90 | 0.83 to 0.97 | 0.008 |
| Ratio of docosahexaenoic acid to total FA (%) | 0.90 | 0.83 to 0.97 | 0.009 |
| Ratio of omega-6 FA to total FA (%) | 0.93 | 0.87 to 1.01 | 0.083 |
| Ratio of linoleic acid to total FA (%) | 0.96 | 0.89 to 1.04 | 0.28 |
| Ratio of conjugated linoleic acid to total FA (%) | 1.03 | 0.95 to 1.11 | 0.53 |
*Cox regression models were performed to estimate association between each metabolites and risk of CVD onset over the 16-y of follow-up. Models were adjusted for age, sex, total energy intake, ethnicity, smoking habits, physical activity, type 2 diabetes, diastolic and systolic blood pressure, use of antihypertensive drugs and use of lipid-lowering drugs.
Figure 3Comparison of diet-metabolites associations and metabolites-incident CVD risk associations in Whitehall II study. Associations directionally concordant. Associations directionally discordant. On the left hand size: Linear regression models estimating the associations between AHEI z-score and the 41 selected metabolites performed in 4824 participants and adjusted for age, sex, total energy intake, ethnicity, smoking habits, physical activity, type 2 diabetes, diastolic and systolic blood pressure, use of antihypertensive drugs and use of lipid-lowering drugs. Results are expressed as linear regression coefficients accompanied with their 95% confidence interval. To facilitate comparison, metabolites were first square root transformed and then standardized to z-scores (mean = 0, SD = 1). On the right hand size: Cox proportional hazards regression models estimating the association between the selected 41 metabolites and the risk of incident CVD over the 15.8 years of follow-up, performed in 5840 Whitehall II participant, adjusted for age, sex, total energy intake, ethnicity, smoking habits, physical activity, type 2 diabetes, diastolic and systolic blood pressure, use of antihypertensive medication. Results are expressed as Hazard Ratio accompanied with their 95% confidence interval. To facilitate comparison, metabolites were first square root transformed and then standardized to z-scores (mean = 0, SD = 1).
Figure 4Metabolomic profiles associated with low adherence to healthy dietary guidelines and with the risk of incident cardiovascular diseases -. The metabolic profiling analyses identified 41 metabolites associated with the adherence to healthy diet in Whitehall II study. Replication analyses in the Young Finns Study showed that most of these diet-metabolites associations were directionally concordant. We then assessed the extent to which each of the 41 metabolites associated with diet score also predicted CVD events over the 15.8 years of Whitehall II Study follow-up. Results showed that most of metabolites associated with poor adherence to healthy dietary guidelines are also related to higher CVD risk and consisted of amino acids, glycoprotein acetyls, size of lipoprotein particule size, lipids in lipoproteins, cholesterol and triglycerides and fatty acids. These findings highlight a specific fatty acid patterns robustly associated with both adherence to healthy diet and reduced risk of CVD. These specific fatty acids pattern consisted of lower levels of saturated and monounsaturated fatty acids and higher ratio of polyunsaturated fatty acids, omega-3 and docosahexaenoic acid relative to total fatty acids concentrations, possibly representing a molecular link between healthy diet and lower cardiovascular disease risk.
Figure 5Flow chart diagram mapping the inclusion of Whitehall II and Young Finns Study participants.